DocDollars

Idorsia Pharmaceuticals Us Inc

PA · United States · Reporting entity ID 100001171891

Total reported 2019–2025
$12.0M
#442 of 2,960 reporting companies — 0% of all reported industry payments
$7.37M in general payments across 117,155 records, plus $4.66M in research funding across 541 records.

How it breaks down

General payments $7,371,134
Research funding $4,657,229

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Idorsia Pharmaceuticals Us Inc reported $12.0M to US doctors and teaching hospitals from 2019 to 2025, ranking #442 of 2,960 reporting companies. 39% of that was research funding and 61% general payments such as consulting, speaking, food and travel. 117,155 general payment records and 541 research records were filed.

Common questions about Idorsia Pharmaceuticals Us Inc

How much has Idorsia Pharmaceuticals Us Inc paid US doctors?

Idorsia Pharmaceuticals Us Inc reported $12,028,363 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $7,371,134 in general payments, $4,657,229 in research funding.

How does Idorsia Pharmaceuticals Us Inc rank among drug and device companies?

It ranks #442 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Idorsia Pharmaceuticals Us Inc mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.